Full Press Release Details
CELLECT BIOTECHNOLOGY
GENERAL MEETING OF SHAREHOLDERS
Notice is hereby given
that an Annual General Meeting (the "Annual Meeting") of Shareholders of Cellect Biotechnology Ltd. (the "Company")
will be held at the offices of the Company's legal counsel - Doron, Tikotzky, Kantor, Gutman, Nass & Amit Gross,
at B.S.R 4 Tower, 33rd Floor, 7 Metsada Street, Bnei Brak, on July 30, 2019 at 11:00 a.m. Israel time or at any postponement or
adjournment thereof.
is being called for the following purposes:
| 5. | To increase the Company's authorized share capital by 500,000,000 ordinary shares, such that following the increase, the authorized share capital shall be 1,000,000,000 ordinary shares, no par value each, and to amend the Company's articles of association accordingly; and | |
| 6. | To present the financial statements of the Company for the fiscal year ended December 31, 2018. |
board of directors recommends that you vote in favor of the proposals, which are described in the attached Proxy Statement.
and American Depositary Share (the "ADSs") holders of record at the close of business on July 2, 2019 (the "Record
Date"), are entitled to notice of and to vote at the Annual Meeting either in person or by appointing a proxy to vote in
their stead at the Annual Meeting. Shareholders and ADS holders are asked to vote on proposals 1 through 5 (inclusive).
registered in the Company's shareholders' register in Israel, and shareholders who hold ordinary shares through members
of the Tel Aviv Stock Exchange, may also vote through the attached proxy by completing, dating, signing and mailing the proxy to
the Company's offices, so that is received by the Company no later than four hours prior to the scheduled date of the Annual
Meeting. Shareholders registered in the Company's shareholders' register in Israel, and shareholders who hold ordinary
shares through members of the Tel Aviv Stock Exchange who vote their ordinary shares by proxy, must also provide the Company with
a copy of their identity card, passport or certification of incorporation, as the case may be. Shareholders who hold shares through
members of the Tel Aviv Stock Exchange and intend to vote their ordinary shares either in person or by proxy must deliver to the
Company, no later than four hours prior to the scheduled date of the Annual Meeting, an ownership certificate confirming their
ownership of the Company's ordinary shares on the Record Date, which certificate must be approved by a recognized financial
institution, as required by the Israeli Companies Regulations (Proof of Ownership of Shares for Voting at General Meeting) 5760
holders should return their proxies by the date set forth on their voting instruction card.
the extent you would like to submit a position statement with respect to any of proposals described in the Proxy Statement pursuant
to the Israeli Companies law, 1999, you may do so by delivery of appropriate notice to Company's offices (Attention: Chief
Financial Officer) located at 23 Hata'as Street Kfar Saba, Israel 44425, Israel, not later than ten days before the extraordinary
meeting date (i.e., July 20, 2019).
you are a beneficial owner of ordinary shares registered in the name of a member of the Tel Aviv Stock Exchange and you wish to
vote, either by appointing a proxy, or in person by attending the Annual Meeting you must deliver to us a proof of ownership in
accordance with the Israeli Companies Law of 1999 and the Israeli Companies Regulations (Proof of Ownership of Shares for Voting
at General Meetings), 5760 - 2000. Detailed voting instructions are provided in the Proxy Statement.
| Sincerely, | |
| Kasbian Nuriel Chirich | |
| Chairman of the Board of Directors | |
| June 25, 2019 |
CELLECT BIOTECHNOLOGY
MEETING OF SHAREHOLDERS
Proxy Statement is furnished to our holders of ordinary shares, without par value, and holders of our ordinary shares that are
represented by American Depository Shares ("ADSs") for the Annual General Meeting (the "Annual Meeting")
of Shareholders of Cellect Biotechnology Ltd. to be held on July 30, 2019 at the offices of the Company's legal counsel,
Doron, Tikotzky, Kantor, Gutman, Nass & Amit Gross., at B.S.R. 4 Tower, 33rd Floor, 7 Metsada Street, Bnei Brak, Israel or
at any adjournments thereof. The Annual Meeting shall be held at 11:00 a.m., Israel time, on such day or at any adjournments
this Proxy Statement, we use terms such as "Cellect", "we", "us", "our" and the
"Company" to refer to Cellect Biotechnology Ltd. and terms such as "you" and "your" to refer
to our shareholders and ADS holders.
agenda of the Annual Meeting will be as follows:
Nuriel Chirich, Dr. Shai Yarkoni, Abraham Nahmias and David Braun to serve as directors until the next annual general meeting of
of compensation of Dr. Shai Yarkoni;
of compensation of Kasbian Nuriel Chirich;
Forer, Gabbay & Kasierer (a member of Ernst & Young Global) as the Company's independent registered public accounting
firm until the next annual general meeting of the Company and to authorize the Company's Board of Directors to determine
its compensation for the fiscal year ending December 31, 2019;
Company's authorized share capital by 500,000,000 ordinary shares, such that following the increase, the
authorized share capital shall be 1,000,000,000 ordinary shares, no par value each, and to amend the
Company's articles of association accordingly; and
To present the financial
statements of the Company for the fiscal year ended December 31, 2018.
currently are unaware of any other matters that may be raised at the Annual Meeting. Should any other matters be properly raised
at the Annual Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.
board of directors unanimously recommends that you vote "FOR" Proposals No. 1 through 5 (inclusive).
shareholders and ADS holders of record at the close of business on July 2, 2019 (the "Record Date"), are entitled to
notice of and to vote at the Annual Meeting and any adjournment or postponement.
can vote your ordinary shares by attending the Annual Meeting. If you do not plan to attend the Annual Meeting, the method of voting
will differ for shares held as a record holder, shares held in "street name" (through a Tel Aviv Stock Exchange, or
TASE, member) and shares underlying ADSs that you hold. Record holders of shares will receive proxy cards. Holders of shares in
"street name" through a TASE member will also vote via a proxy card, but through a different procedure (as described
below). Holders of ADSs (whether registered in their name or in "street name") will receive voting instruction cards
in order to instruct their banks, brokers or other nominees on how to vote.
you are a shareholder holder of record, you can submit your vote by completing, signing and submitting an applicable proxy card,
which has been published at www.sec.gov.
follow the instructions on the applicable proxy card.
Holding in "Street Name," Through the TASE
you hold ordinary shares in "street name," that is, through a bank, broker or other nominee that is admitted as a member
of the TASE, your shares will only be voted if you provide the attached proxy by completing, dating, signing and mailing the proxy
to the Company's offices, so that it is received by the Company no later than four hours prior to the scheduled date of the
Annual Meeting, or if you attend the Annual Meeting in person.
voting by mail, you must sign and date an applicable proxy card in the form filed by us on www.sec.gov, so that it is received
by the Company no later than four hours prior to the scheduled date of the Annual Meeting, and attach to it a certificate signed
by the TASE Clearing House member through which the shares are held, which complies with the Israel Companies Regulations (Proof
of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares, as applicable, on the record date, and return
the applicable proxy card, along with the proof of ownership certificate, to us, as described in the instructions available on
you choose to attend the Annual Meeting (where ballots will be provided), you must bring the proof of ownership certificate from
the TASE's Clearing House member through which the shares are held, indicating that you were the beneficial owner of the
shares, as applicable, on the record date.
the terms of the Deposit Agreement between the Company, The Bank of New York Mellon, as depositary ("BNY Mellon"),
and the holders of our ADSs, BNY Mellon shall endeavor (insofar as is practicable) to vote or cause to be voted the number of ordinary
shares represented by ADSs in accordance with the instructions provided by the holders of ADSs to BNY Mellon. For ADSs that are
held in "street name", through a bank, broker or other nominee, the voting process will be based on the underlying
beneficial holder of the ADSs directing the bank, broker or other nominee to arrange for BNY Mellon to vote the ordinary shares
represented by the ADSs in accordance with the beneficial holder's voting instructions. If no instructions are received by
BNY Mellon from any holder of ADSs (whether held directly by a beneficial holder or in "street name") with respect
to any of the shares represented by the ADSs on or before the date established by BNY Mellon for such purpose, BNY Mellon shall
not vote or attempt to vote the shares represented by such ADSs.
Record Holders or Accounts
may receive more than one set of voting materials, including multiple copies of this document and multiple proxy cards or voting
instruction cards. For example, shareholders who hold ADSs in more than one brokerage account will receive a separate voting instruction
card for each brokerage account in which ADSs are held. Shareholders of record whose shares are registered in more than one name
will receive more than one proxy card. You should complete, sign, date and return each proxy card and voting instruction card you
board of directors urges you to vote your shares so that they will be counted at the Annual Meeting or at any postponements or
adjournments of the Annual Meeting.
appointing "proxies", shareholders and ADS holders may vote at the Annual Meeting whether or not they attend. If a
properly executed proxy in the attached form is received by us at least four hours prior to the Annual Meeting (and received by